The 4 most recent market catalysts affecting $INDV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 95
Indivior Announces $8.13/Share Special Cash Dividend, Payable On Or About November 6 To Holders Of Record October 30, Contingent On Closing Of Supernus Merger
The announcement of an $8.13/share special cash dividend for Indivior is a major positive catalyst for its shareholders, representing a significant return of capital. However, this…
Aug 5, 2026
Market Technicals
Bearish
Impact 55
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43
Barclays analyst Glen Santangelo maintained an 'Overweight' rating on Indivior Pharmaceuticals (INDV), signaling continued confidence in the company's fundamentals. However, the pr…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est
Indivior Pharmaceuticals (INDV) has raised its FY2026 sales outlook from a previous range of $1.215 billion-$1.285 billion to a new range of $1.295 billion-$1.365 billion. This upw…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 85
Indivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M Estimate
This headline is a significant corporate catalyst for Indivior. The substantial beat on both adjusted EPS and sales estimates suggests stronger-than-anticipated product demand or b…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.